HPS Pharmacies wish to advise that Pfizer has discontinued Hyoscine Hydrobromide ampoules as follows:

DBL™ Hyoscine Hydrobromide Ampoules
Hyoscine Hydrobromide 400 mcg/1mL
ARTG 16347

There is currently not an Australian-registered product that is a direct substitute for this product. Hyoscine butylbromide ampoules remain available. However, as the butylbromide salt does not readily cross the blood-brain barrier, it lacks the central effects of hyoscine hydrobromide.

An internationally registered hyoscine hydrobromide 400mcg/mL product may be available via the Special Access Scheme (SAS). Please note that this product is subject to a longer lead-time and different pricing as it must be sourced internationally.

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Pfizer on 1800 675 229 or your pharmacist at HPS Pharmacies.


Download PDF

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates